Correlation between Coronary Artery Disease and the Level of Serum Lectin-like Oxidized Low-density Lipoprotein Receptor-1 and Its Polymorphism
|School||Tianjin Medical University|
|Keywords||Coronary heart disease Acute coronary syndrome Lectin-like oxidized low-density lipoprotein receptor-1 Percutaneous coronary intervention treatment Single nucleotide polymorphisms|
With the increasing standard of living, improved diet and lifestyle changes, coronary heart disease (coronary artery disease, CAD) incidence was significantly higher. Is now generally believed that coronary heart disease is a chronic inflammatory disease, atherosclerosis (AS) is the basis of its occurrence. Oxidation of low-density lipoprotein (ox-LDL) is considered as an independent risk factor for coronary heart disease, is caused by atherosclerosis initiating factor. Discovered in recent years a new type of ox-LDL receptor - hemagglutination - like oxidized low-density lipoprotein receptor -1 (of LOX-1) by vascular endothelial promote inflammation, accelerated apoptosis and foam cell formation mechanisms to promote atherosclerosis, leading to the occurrence of coronary heart disease development. Scavenger receptor found only LOX-1 exists in soluble form. Blood soluble LOX-1 (sLOX-1) levels may reflect the extent of the membrane surface LOX-1 expression, and thus reflects a certain disease states, LOX-1 detection hope to play a role in the diagnosis and prevention of coronary heart disease. Objective:. Detect the research object serum in sLOX-1 level, to predict the occurrence of coronary heart disease, the impact of development; 2. Detection study genetic polymorphism of LOX-1 3'-UTR of 188 sites to explore LOX-1 gene polymorphism and coronary heart disease; 3. investigate the correlation of serum-derived sLOX-1 and LOX-1 3'-UTR 188 gene polymorphism. Methods: 1. Study selected 121 cases of patients with coronary artery disease, percutaneous coronary intervention the therapeutic (PCI), including acute coronary syndrome (ACS) 75 patients with stable angina pectoris (SAP) 46 cases; 50 patients were treated by coronary angiography (CAG) investigation. Measured by enzyme-linked immunosorbent assay (ELISA) was selected by admission instantly ACS group and SAP group after PCI immediately CAG control group immediately after one week of the ACS group and SAP group after PCI concentration of serum sLOX-1; 2. additional cases in the first part of the study on the basis of the total study subjects were divided into 2 groups, 170 cases of coronary heart disease group were confirmed by CAG diagnosed; control group, 140 cases were confirmed by CAG troubleshoot. Polymerase chain reaction - restriction fragment length polymorphism (PCR-RFLP) method on the total study LOX-1 gene 3'-UTR188, locus polymorphism analysis, comparing the gene polymorphism in the two groups. distribution and its relationship with coronary heart disease. Results: 1. Admission instantly and immediately after the ACS group peripheral serum sLOX-1 level higher than the SAP group and control group, SAP group was higher (P lt; 0.05); PCI after one week, the ACS group and SAP differences between the two groups was not statistically significant (P gt; 0.05). Within each group compared three groups of immediate postoperative serum sLOX-level and admission instantly compared the difference was not statistically significant (P gt; 0.05); the PCI one week after the serum level sLOX-1 than admission instantly decreased , but the difference was not statistically significant (P gt; 0.05) 2.LOX-1 gene 3'-UTR of 188 sites there are three genotypes: CC, CT and TT. CHD group, CC, CT and TT genotype frequencies were 47.65%, 42.35% and 10.00%, respectively; genotype frequency of the control group were 54.29%, 36.43% and 9.28%, respectively; by z2 inspection, different genotype frequencies in the two The distribution group no significant difference (P gt; 0.05). 188 C allele frequency in the CHD group and control group were 68.82%, 72.50%; 188 points T allele frequency in the CHD group and control group were 31.18%, 27.50%, χ2 test there was no significant difference (P gt; 0.05). 3 This study shows, the CHD group, CC, CT TT genotype corresponding to serum sLOX-1 levels were 193.09 ± 35.80μg / L from 208.03 ± 45.84μg / L; corresponding control group CC, CT TT genotype Blood. clear sLOX-1 levels were 144.53 ± 30.02μg / L, 164.39 ± 19.36μg / L. Genotype corresponding serum sLOX-1 levels within each group showed no statistically significant difference (P gt; 0.05), suggesting that no significant correlation between the serum levels of sLOX-1 gene polymorphism of the 3'-UTR. Conclusion: 1. Serum levels of LOX-1 level increased, suggesting that there is significant oxidation of LDL; oxidative modification of ACS patients was significantly stronger than in patients with SAP, inferred LOX-1 expression in unstable plaques ten stable plaque , suggesting that LOX-1 associated with the formation of unstable plaque, as serological markers predict unstable plaque; 2. serum levels of LOX-1 by mechanical damage, ischemia - reperfusion injury, these injuries can lead to serum LOX-1 levels; 3. serum LOX-1 level of the number of coronary lesions unrelated, and can not be used as the reference indicator of the severity of coronary artery disease; 4 gene polymorphism LOX-1 3'-UTR of 188 sites in the crowd and coronary heart disease incidence was no significant correlation, not as a predictor of coronary heart disease; 5. serum LOX-1 level of LOX-1 3'-UTR of 188 gene polymorphism no significant correlation.